🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    3 trials

  2. Rituximab

    The First People's Hospital of Lianyungang

    Refractory Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. Rituximab

    United Therapeutics Europe Ltd

    Kidney Transplant Rejection

    phase 3 small molecule terminated

    1 trial

  4. Rituximab

    Hospital Authority, Hong Kong

    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    phase 3 mab completed

    1 trial

  5. Robotic Gastrectomy

    The First People's Hospital of Lianyungang

    Gastric Cancer (GC)

    phase 3 other active

    1 trial

  6. Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)

    Chiesi Farmaceutici S.p.A

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  7. Romiplostim

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  8. Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable

    The George Institute

    lumbar arthrodesis

    phase 3 small molecule active

    1 trial

  9. Roux-en-Y anastomosis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  10. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  11. S-1 therapy

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  12. SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs

    phase 3 small molecule active

    1 trial

  13. SARS-CoV-2 Vaccine (Vero Cell), Inactivated

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 3 mab completed

    1 trial

  14. SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. SODIUM CHLORIDE, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  16. SP, chloroquine, amodiaquine, primaquine, artesunate

    United Therapeutics Europe Ltd

    Malaria

    phase 3 small molecule completed

    1 trial

  17. SP-102

    Semnur Pharmaceuticals

    Lumbosacral Radicular Pain

    phase 3 small molecule active

    3 trials

  18. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  19. SPD465

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    2 trials

  20. SPD476

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  21. SPD476 (1.2g)

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  22. SPD476 (mesalazine)

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  23. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  24. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources